Show simple item record

Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases

dc.contributor.authorJohn R. van Sörnsen de Koste
dc.contributor.authorClaire C. van Vliet
dc.contributor.authorFamke L. Schneiders
dc.contributor.authorAnna M.E. Bruynzeel
dc.contributor.authorBerend J. Slotman
dc.contributor.authorMiguel A. Palacios
dc.contributor.authorSuresh Senan
dc.contributor.otherCorresponding author.; Department of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
dc.contributor.otherDepartment of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
dc.contributor.otherDepartment of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
dc.contributor.otherDepartment of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
dc.contributor.otherDepartment of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
dc.contributor.otherDepartment of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
dc.contributor.otherDepartment of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
dc.date.accessioned2025-10-09T04:52:57Z
dc.date.available2025-10-09T04:52:57Z
dc.date.issued01-10-2021
dc.identifier.urihttp://www.sciencedirect.com/science/article/pii/S2405631621000518
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/40818
dc.description.abstractStereotactic ablative radiotherapy (SABR) planning for adrenal metastases aims to minimize doses to the adjacent kidney. Renal dose constraints for SABR delivery are not well defined. In 20 patients who underwent MR-guided breath-hold SABR in five daily fractions of 8–10 Gy, ipsilateral renal volumes receiving ≥20 Gy best correlated with loss of renal volumes, with median renal volume reduction being 6% (range: 3%-11%, 10th-90th percentiles). Organ function did not deteriorate in 18 patients, who had post treatment renal function tests available. This suggests that the ipsilateral renal volume receiving 20 Gy can be used as partial organ dose constraint for SABR to targets in the upper abdomen.
dc.language.isoEN
dc.publisherElsevier
dc.subject.lccMedical physics. Medical radiology. Nuclear medicine
dc.titleRenal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases
dc.typeArticle
dc.description.keywordsSABR
dc.description.keywordsAdrenal
dc.description.keywordsKidney
dc.description.keywordsOrgan at Risk
dc.description.keywordsRenal dose constraints
dc.description.pages1-4
dc.description.doi10.1016/j.phro.2021.09.001
dc.title.journalPhysics and Imaging in Radiation Oncology
dc.identifier.oaioai:doaj.org/journal:1cdac17d13dd4204ae743f7507b8213a


This item appears in the following Collection(s)

Show simple item record